Unfortunately, there are lots of firms which do not take a framework-driven approach. Many look ups are haphazard, where companies search for anything with a confident revenue potential, or anything that can be sold by their existing sales and marketing facilities. In our experience, any approach which aims to simply give you the sales organization with products distribute is unsustainable ultimately.
Savvy BD&L executives can leverage consultancies to aid them develop this overarching composition, identifying the key variables that happens to be important to the corporation, its management, and its shareholders. Pharmaceutical management consultants can bring an objective perspective to an exercise which, if accomplished properly, results in a roadmap that this BD&L team can after that use to plan together with execute a BD&L tactical plan.
Broaden Skill Set - We have noticed that many smaller BD&L teams have strengths and skills in certain areas, but not some others. For example, some companies have BD&L clubs led by scientists or clinicians or attorneys who lack the feeling to quantitatively and in financial terms assess opportunities. Using a consultancy can supply unbiased, rigorous quantitative analysis and financial modeling.
Extend Geographic Breadth and Depth - The standard model for US together with EU companies was to help license drugs from Japanese companies, because many innovative Japanese people companies lacked the global presence to develop and market their innovations outside their home country.
Today, this is not a longer the case. Many Japanese companies, such since Takeda and Eisai, have successfully established a study and commercial presence the united states and EU. Companies like this no longer need West pharmaceutical companies to commercialize their own internally-developed innovations. So Western pharmaceutical companies are traveling to and meeting with companies in China, India, and Eastern Europe... anywhere where a new innovation or chance may exist. For larger, global BD&L teams this is less of an issue. IN fact, the largest companies typically have regionally focused BD&L executives who consentrate on identifying opportunities from their local markets because of their local or even universal markets. But what of the smaller companies which may lack this geographic facilities?
This is precisely when consultants, especially boutique, highly focused consultancies, can play a decisive role in sourcing together with identifying opportunities that fit in the strategic and financial objectives in the company. A consulting firm can are a de facto seeker and "shopper" of chance. Consultants can be utilized to focus on particular geographic areas for specific ideas. Examples may include:
> Specialty and generic companies generating $100 MM with Central and South America
> Sector expansion in Central and Eastern Countries in europe such as Austria, Czech Republic, and Poland
> The acquisition of pharmaceutical companies in India
> Usage of patented drug delivery technologies
A compact team can leverage consultants to immediately expand their collective reach, thereby identifying unique opportunities which would otherwise never be diagnosed. Importantly, many of these opportunities outside of the US/EU will never appear on sites which publish BD&L options. Oftentimes the possibility of a transaction is not considered before party is actually approached with an indication of interest. A good consultant can play an important role in opening these doors which were heretofore closed.
It is understandable that many senior executives may have a mistrust or a prejudice against using management consultants.
china sourcing consultant